Securities code: Hvsen Biotechnology Co.Ltd(300871) securities abbreviation: Hvsen Biotechnology Co.Ltd(300871) Announcement No.: 2022018 convertible bond Code: 123132 convertible bond abbreviation: Huisheng convertible bond
Hvsen Biotechnology Co.Ltd(300871)
Announcement on profit distribution plan in 2021
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
Hvsen Biotechnology Co.Ltd(300871) (hereinafter referred to as “the company”) held the 23rd Meeting of the second board of directors and the 20th meeting of the second board of supervisors on March 10, 2022, and deliberated and adopted the proposal on the company’s profit distribution plan in 2021. This proposal needs to be submitted to the 2021 annual general meeting of shareholders of the company for deliberation. The independent directors of the company expressed their independent opinions on the profit distribution plan. Relevant matters are hereby announced as follows:
1、 Basic contents of 2021 profit distribution plan
Audited by Zhongshen Zhonghuan Certified Public Accountants (special general partnership), the company realized a net profit of 13286553422 yuan attributable to shareholders of Listed Companies in 2021, plus 31161607669 yuan of undistributed profit at the beginning of 2021, minus 1732052552 yuan of statutory surplus reserve and 4530787738 yuan of cash dividend in 2020, The profit available for distribution to shareholders in the consolidated statements of the listed company is 38185320801 yuan, and the profit available for distribution to shareholders of the parent company is 32767905382 yuan.
In view of the company’s current stable operation, good cash flow and future strategic development vision, in order to share the operating results of the company’s development with all shareholders, on the premise of comprehensively considering the company’s profitability, financial status, normal operation and long-term development, In accordance with the company law, the articles of association and the shareholder return plan for Hvsen Biotechnology Co.Ltd(300871) next three years (20212023), the board of directors of the company has proposed the following profit distribution plan for 2021: it is proposed to distribute a cash dividend of RMB 3.31 (including tax) to all shareholders for every 10 shares based on the total issued share capital of 166248527 shares as of December 31, 2021, No bonus shares will be given, and no capital reserve will be converted into share capital. A total cash dividend of 5502826244 yuan (including tax) will be distributed, and the remaining undistributed profits will be carried forward to subsequent years.
According to regulations, from the date of disclosure of the company’s profit distribution plan to the date of equity distribution and equity registration, if the total shares of shareholders entitled to profit distribution change due to the issuance of new shares, equity incentive exercise, convertible bonds to shares, share repurchase and other reasons, the company will adjust the distribution proportion according to the principle of unchanged total profit distribution.
2、 Description of legality and compliance of profit distribution plan
On the premise of ensuring the normal operation and long-term development of the company, the profit distribution plan for 2021 is put forward by comprehensively considering the reasonable demands and investment returns of the majority of investors. It matches the operating performance and future development of the company, will not cause the shortage of working capital or other adverse effects of the company, and is conducive to the majority of investors to participate in the development of the company and share the operating results, Comply with the relevant provisions of the company law, the guidelines for the supervision of listed companies No. 3 – cash dividends of listed companies, the articles of association and the company’s profit distribution policy, and have legitimacy, compliance and rationality.
3、 Decision making procedure
(I) opinions of the board of directors
The board of Directors believes that the company’s profit distribution plan for 2021 comprehensively considers the company’s current share capital structure, profitability, financial status and the reasonable demands of the majority of investors, which is conducive to all shareholders to share the operating results of the company’s development and enhance shareholders’ confidence, Comply with laws and administrative regulations such as the guidelines for the supervision of listed companies No. 3 – cash dividends of listed companies, the guidelines for the self discipline supervision of listed companies No. 2 – standardized operation of companies listed on the gem of Shenzhen Stock Exchange, the articles of association, the shareholder return plan for the Hvsen Biotechnology Co.Ltd(300871) next three years (20212023), etc, The board of directors agreed to the company’s profit distribution plan for 2021, and agreed to submit this proposal to the company’s 2021 annual general meeting of shareholders for deliberation, and requested the general meeting of shareholders to authorize the board of directors to handle specific matters related to this equity distribution.
(II) opinions of the board of supervisors
The board of supervisors believes that the company’s profit distribution plan for 2021 comprehensively considers the company’s current share capital structure, profitability, financial status and the reasonable demands of the majority of investors, which is conducive to all shareholders to share the operating results of the company’s development and enhance shareholders’ confidence, In line with the relevant provisions of the guidelines for the supervision of listed companies No. 3 – cash dividends of listed companies, the guidelines for the self discipline supervision of listed companies No. 2 – standardized operation of companies listed on the gem of Shenzhen Stock Exchange, the articles of association and the plan for shareholder returns in the Hvsen Biotechnology Co.Ltd(300871) next three years (20212023)), the board of supervisors unanimously agreed on the company’s profit distribution plan for 2021.
(III) opinions of independent directors
The independent directors believe that the profit distribution plan of the company in 2021 complies with the relevant provisions of the company law, the guidelines for the supervision of listed companies No. 3 – cash dividends of listed companies, the guidelines for the self discipline supervision of listed companies No. 2 of Shenzhen Stock Exchange – standardized operation of GEM listed companies, the articles of association, profit distribution policies and so on, The company’s current equity structure, profitability and financial situation are comprehensively considered to match the company’s operating performance and scale; Fully consider the reasonable demands of the majority of investors, which is conducive to all shareholders to share the operating results of the company’s development and enhance shareholders’ confidence; It is conducive to the sustained, stable and healthy development of the company, and there is no situation that damages the interests of the company and shareholders, especially small and medium-sized shareholders. All independent directors unanimously agreed on this profit distribution plan and agreed to submit this proposal to the 2021 annual general meeting of shareholders of the company for deliberation.
4、 Other relevant matters
This profit distribution plan still needs to be submitted to the 2021 annual general meeting of the company for deliberation. There is uncertainty. Please pay attention to and pay attention to the investment risks.
5、 Documents for future reference
(I) resolutions of the 23rd Meeting of the second board of directors;
(II) resolutions of the 20th meeting of the second board of supervisors;
(III) independent opinions of independent directors on matters related to the 23rd Meeting of the second board of directors. It is hereby announced.
Hvsen Biotechnology Co.Ltd(300871) board of directors March 11, 2022
